Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Seagen Inc (NQ: SGEN )

207.08 +0.09 (+0.04%)
Streaming Delayed Price Updated: 3:36 PM EDT, Sep 21, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 495,741
Open 206.50
Bid (Size) 207.06 (4)
Ask (Size) 207.13 (1)
Prev. Close 206.99
Today's Range 206.00 - 207.54
52wk Range 116.08 - 210.50
Shares Outstanding 181,934,500
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
(SGEN) - Analyzing Seagen's Short Interest
Via Benzinga
Flee to Healthcare Stocks if Recession Rears its Head?
In uncertain economic conditions, healthcare stocks can be a refuge due to steady demand and favorable inflation conditions. Many also offer dividends. 
Via MarketBeat
Topics Economy
Exposures Economy Interest Rates

Performance

YTD
+60.90%
+60.90%
1 Month
+7.13%
+7.13%
3 Month
+4.25%
+4.25%
6 Month
+4.39%
+4.39%
1 Year
+45.84%
+45.84%

More News

Read More
Check Out What Whales Are Doing With SGEN
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Why Shares of Iovance Biotherapeutics Dropped Thursday
Via The Motley Fool
Check Out What Whales Are Doing With SGEN
Via Benzinga
$1000 Invested In This Stock 15 Years Ago Would Be Worth $16,000 Today
Via Benzinga
Check Out What Whales Are Doing With SGEN
Via Benzinga
The 3 Most Undervalued Pharma Stocks to Buy in September 2023
Via InvestorPlace
Why Is Cancer Focused Nurix Therapeutics Stock Trading Higher Today?
Via Benzinga
Pyxis Oncology M&A Spotlight Signals Potential Growth Amidst Competitive ADC Landscape: Analyst
Via Benzinga
Why Shares of Zai Lab Limited Were Jumping on Tuesday
Via The Motley Fool
Encouraging Data From Seagen/Genmab's Cervical Cancer Study - Tivdak Success Sets Stage For New Indications
Via Benzinga
Looking Into Seagen's Recent Short Interest
Via Benzinga
Here's How Much You Would Have Made Owning Seagen Stock In The Last 10 Years
Via Benzinga
If You Invested $100 In This Stock 15 Years Ago, You Would Have $1,600 Today
Via Benzinga
Seagen and Genmab Announce TIVDAK® (tisotumab vedotin-tftv) Improved Overall Survival in Patients With Recurrent or Metastatic Cervical Cancer Compared With Chemotherapy Alone
From Seagen Inc.
Via Business Wire
Genmab and Seagen Announce That TIVDAK® (tisotumab vedotin-tftv) Met its Primary Endpoint of Improved Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared to Chemotherapy
From Genmab A/S
Via Business Wire
Ambrx Biopharma Has Surged 483% This Year. But It Could Just Be Getting Started.
Via Investor's Business Daily
3 Fantastic Stocks to Buy in a New Bull Market
Via The Motley Fool
How To Invest In The Healthcare Sector
Via Talk Markets
Seagen's Positive Trial Outcomes: Analyst Says The Update Might Double Tukysa's Current Market
Via Benzinga
Win For Pfizer? Seagen's Cancer Combo Therapy Hits Primary Goal In Late-Stage Breast Cancer Study
Via Benzinga
Seagen Phase 3 Trial of TUKYSA® (tucatinib) in Combination with Antibody-Drug Conjugate ado-trastuzumab emtansine Meets Primary Endpoint of Progression-Free Survival in Patients with Previously Treated HER2-Positive Metastatic Breast Cancer
From Seagen Inc.
Via Business Wire
3 Pharmaceutical Stocks to Buy and Hold for the Long Haul
Via MarketBeat
Exposures COVID-19
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.